These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28859044)

  • 1. Vincristine, Irinotecan, and Bevacizumab in Relapsed Wilms Tumor With Diffuse Anaplasia.
    Schiavetti A; Varrasso G; Collini P; Clerico A
    J Pediatr Hematol Oncol; 2018 May; 40(4):331-333. PubMed ID: 28859044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab.
    Venkatramani R; Malogolowkin MH; Mascarenhas L
    Pediatr Blood Cancer; 2014 Apr; 61(4):756-9. PubMed ID: 24115645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group.
    Green DM; Beckwith JB; Breslow NE; Faria P; Moksness J; Finklestein JZ; Grundy P; Thomas PR; Kim T; Shochat S
    J Clin Oncol; 1994 Oct; 12(10):2126-31. PubMed ID: 7931483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance chemotherapy to reduce the risk of a metachronous Wilms tumor in children with bilateral nephroblastomatosis.
    Ortiz MV; Fernandez-Ledon S; Ramaswamy K; Forlenza CJ; Shukla NN; Kobos R; Heaton TE; LaQuaglia MP; Steinherz PG
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27500. PubMed ID: 30334607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study.
    Tournade MF; Com-Nougué C; de Kraker J; Ludwig R; Rey A; Burgers JM; Sandstedt B; Godzinski J; Carli M; Potter R; Zucker JM;
    J Clin Oncol; 2001 Jan; 19(2):488-500. PubMed ID: 11208843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focal versus diffuse anaplasia in Wilms tumor--new definitions with prognostic significance: a report from the National Wilms Tumor Study Group.
    Faria P; Beckwith JB; Mishra K; Zuppan C; Weeks DA; Breslow N; Green DM
    Am J Surg Pathol; 1996 Aug; 20(8):909-20. PubMed ID: 8712292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
    Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
    J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New definitions of focal and diffuse anaplasia in Wilms tumor: the International Society of Paediatric Oncology (SIOP) experience.
    Vujanić GM; Harms D; Sandstedt B; Weirich A; de Kraker J; Delemarre JF
    Med Pediatr Oncol; 1999 May; 32(5):317-23. PubMed ID: 10219330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
    Dome JS; Cotton CA; Perlman EJ; Breslow NE; Kalapurakal JA; Ritchey ML; Grundy PE; Malogolowkin M; Beckwith JB; Shamberger RC; Haase GM; Coppes MJ; Coccia P; Kletzel M; Weetman RM; Donaldson M; Macklis RM; Green DM
    J Clin Oncol; 2006 May; 24(15):2352-8. PubMed ID: 16710034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.
    Green DM; Breslow NE; Beckwith JB; Finklestein JZ; Grundy PE; Thomas PR; Kim T; Shochat SJ; Haase GM; Ritchey ML; Kelalis PP; D'Angio GJ
    J Clin Oncol; 1998 Jan; 16(1):237-45. PubMed ID: 9440748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of patients with stage I focal anaplastic and diffuse anaplastic Wilms tumour: A report from the SIOP-WT-2001 GPOH and UK-CCLG studies.
    Mifsud W; Furtwängler R; Vokuhl C; D'Hooghe E; Pritchard-Jones K; Graf N; Vujanić GM
    Eur J Cancer; 2022 May; 166():1-7. PubMed ID: 35255331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Wilms' tumour of unfavorable histology--results of treatment with the SIOP 93-01 protocol at the Gdańsk centre. Preliminary report].
    Stefanowicz J; Sierota D; Balcerska A; Stoba C
    Med Wieku Rozwoj; 2004; 8(2 Pt 1):197-200. PubMed ID: 15738594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.
    Malogolowkin M; Cotton CA; Green DM; Breslow NE; Perlman E; Miser J; Ritchey ML; Thomas PR; Grundy PE; D'Angio GJ; Beckwith JB; Shamberger RC; Haase GM; Donaldson M; Weetman R; Coppes MJ; Shearer P; Coccia P; Kletzel M; Macklis R; Tomlinson G; Huff V; Newbury R; Weeks D;
    Pediatr Blood Cancer; 2008 Feb; 50(2):236-41. PubMed ID: 17539021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
    Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
    Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for local recurrence in Wilms tumour and the potential influence of biopsy - the United Kingdom experience.
    Irtan S; Jitlal M; Bate J; Powis M; Vujanic G; Kelsey A; Walker J; Mitchell C; Machin D; Pritchard-Jones K;
    Eur J Cancer; 2015 Jan; 51(2):225-32. PubMed ID: 25465191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephroblastomatosis update.
    Laberge JM
    Med Pediatr Oncol; 2003 Jul; 41(1):96-7. PubMed ID: 12764764
    [No Abstract]   [Full Text] [Related]  

  • 17. Bilateral Wilms' tumor with anaplasia: lessons from the National Wilms' Tumor Study.
    Hamilton TE; Green DM; Perlman EJ; Argani P; Grundy P; Ritchey ML; Shamberger RC
    J Pediatr Surg; 2006 Oct; 41(10):1641-4. PubMed ID: 17011261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial.
    de Kraker J; Graf N; van Tinteren H; Pein F; Sandstedt B; Godzinski J; Tournade MF;
    Lancet; 2004 Oct 2-8; 364(9441):1229-35. PubMed ID: 15464183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preservation of anaplastic features in Wilms' tumors after preoperative chemotherapy.
    Alvarez-Silvan AM; Gavilan Carrasco F; Pineda Cuevas G; Andrade Becerra E; Anguita ML; Martinez Caro A; Gracia Valles MC; Maillo Arcega MA
    Med Pediatr Oncol; 1989; 17(2):131-3. PubMed ID: 2539546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
    Robles AJ; Kurmasheva RT; Bandyopadhyay A; Phelps DA; Erickson SW; Lai Z; Kurmashev D; Chen Y; Smith MA; Houghton PJ
    Clin Cancer Res; 2020 Jun; 26(12):3012-3023. PubMed ID: 32184294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.